{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:06:35Z","timestamp":1791389195973,"version":"4.3.3"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13000-019-0802-8","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T09:02:59Z","timestamp":1554800579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2385-8128","authenticated-orcid":false,"given":"Matthew D.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Halfpenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"issue":"suppl_4","key":"802_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011\u20132015. Neuro-Oncology. 2018;20(suppl_4):iv1\u2013iv86.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"802_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.path.2014.10.003","volume":"8","author":"J Phillips","year":"2015","unstructured":"Phillips J, Tihan T, Fuller G. Practical molecular pathology and histopathology of embryonal tumors. Surg Pathol Clin. 2015;8(1):73\u201388.","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"802_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/nan.12459","volume":"44","author":"TJ Stone","year":"2018","unstructured":"Stone TJ, Rowell R, Jayasekera BAP, Cunningham MO, Jacques TS. Review: molecular characteristics of long-term epilepsy-associated tumours (LEATs) and mechanisms for tumour-related epilepsy (TRE). Neuropathol Appl Neurobiol. 2018;44(1):56\u201369.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"12","key":"802_CR4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrneurol.2016.173","volume":"12","author":"I Blumcke","year":"2016","unstructured":"Blumcke I, Aronica E, Becker A, Capper D, Coras R, Honavar M, et al. Low-grade epilepsy-associated neuroepithelial tumours - the 2016 WHO classification. Nat Rev Neurol. 2016;12(12):732\u201340.","journal-title":"Nat Rev Neurol"},{"issue":"4\u20135","key":"802_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000120262","volume":"12","author":"OT Bailey","year":"1985","unstructured":"Bailey OT. Genesis of the Percival Bailey-Cushing classification of gliomas. Pediatr Neurosci. 1985;12(4\u20135):261\u20135.","journal-title":"Pediatr Neurosci"},{"issue":"4","key":"802_CR6","doi-asserted-by":"publisher","DOI":"10.3171\/foc.2005.18.4.8","volume":"18","author":"S Ferguson","year":"2005","unstructured":"Ferguson S, Lesniak MS. Percival Bailey and the classification of brain tumors. Neurosurg Focus. 2005;18(4):e7.","journal-title":"Neurosurg Focus"},{"key":"802_CR7","volume-title":"A classification of the tumors of the glioma group on a Histogenetic basis with a correlated study of prognosis","author":"P Bailey","year":"1926","unstructured":"Bailey P, Cushing H. A classification of the tumors of the glioma group on a Histogenetic basis with a correlated study of prognosis. Philadelphia: Lippincott; 1926."},{"issue":"19","key":"802_CR8","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/jnci\/90.19.1473","volume":"90","author":"JG Cairncross","year":"1998","unstructured":"Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"5897","key":"802_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807\u201312.","journal-title":"Science"},{"issue":"10145","key":"802_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(18)30990-5","volume":"392","author":"S Lapointe","year":"2018","unstructured":"Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432\u201346.","journal-title":"Lancet"},{"issue":"26","key":"802_CR11","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499\u2013508.","journal-title":"N Engl J Med"},{"issue":"26","key":"802_CR12","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"N Cancer Genome Atlas Research","year":"2015","unstructured":"Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481\u201398.","journal-title":"N Engl J Med"},{"issue":"5","key":"802_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00401-015-1409-0","volume":"129","author":"M Weller","year":"2015","unstructured":"Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, et al. Molecular classification of diffuse cerebral WHO grade II\/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015;129(5):679\u201393.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"802_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"key":"802_CR15","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. World Health Organization histological classification of Tumours of the central nervous system. France: International Agency for Research on Cancer; 2016."},{"issue":"2","key":"802_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/nan.12432","volume":"44","author":"P Wesseling","year":"2018","unstructured":"Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139\u201350.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"802_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00428-017-2181-4","volume":"471","author":"SP Ferris","year":"2017","unstructured":"Ferris SP, Hofmann JW, Solomon DA, Perry A. Characterization of gliomas: from morphology to molecules. Virchows Arch. 2017;471(2):257\u201369.","journal-title":"Virchows Arch"},{"issue":"7","key":"802_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nrclinonc.2016.204","volume":"14","author":"G Reifenberger","year":"2017","unstructured":"Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017;14(7):434\u201352.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"802_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/path.4813","volume":"241","author":"JC Chiang","year":"2017","unstructured":"Chiang JC, Ellison DW. Molecular pathology of paediatric central nervous system tumours. J Pathol. 2017;241(2):159\u201372.","journal-title":"J Pathol"},{"issue":"3","key":"802_CR20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/PAP.0000000000000186","volume":"25","author":"JE Velazquez Vega","year":"2018","unstructured":"Velazquez Vega JE, Brat DJ. Incorporating advances in molecular pathology into brain tumor diagnostics. Adv Anat Pathol. 2018;25(3):143\u201371.","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"802_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/nan.12397","volume":"44","author":"F Sahm","year":"2018","unstructured":"Sahm F, Reuss DE, Giannini C. WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours. Neuropathol Appl Neurobiol. 2018;44(2):163\u201371.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"802_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/B978-0-12-802997-8.00006-2","volume":"134","author":"K Masui","year":"2016","unstructured":"Masui K, Mischel PS, Reifenberger G. Molecular classification of gliomas. Handb Clin Neurol. 2016;134:97\u2013120.","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"802_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521\u201335.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"802_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bpa.12171","volume":"24","author":"DN Louis","year":"2014","unstructured":"Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, et al. International society of neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24(5):429\u201335.","journal-title":"Brain Pathol"},{"issue":"3","key":"802_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00401-018-1808-0","volume":"135","author":"DN Louis","year":"2018","unstructured":"Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, et al. cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol. 2018;135(3):481\u20134.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"802_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-016-1646-x","volume":"133","author":"DN Louis","year":"2017","unstructured":"Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, et al. Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol. 2017;133(1):1\u20133.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"802_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bpa.12457","volume":"27","author":"DN Louis","year":"2017","unstructured":"Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, et al. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2017;27(6):851\u20132.","journal-title":"Brain Pathol"},{"issue":"4","key":"802_CR28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-018-1826-y","volume":"135","author":"DN Louis","year":"2018","unstructured":"Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma\/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018;135(4):639\u201342.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"802_CR29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","volume":"136","author":"DJ Brat","year":"2018","unstructured":"Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for \"diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\". Acta Neuropathol. 2018;136(5):805\u201310.","journal-title":"Acta Neuropathol"},{"key":"802_CR30","volume-title":"A Diagnostic Approach","author":"Practical Surgical Neuropathology","year":"2018","unstructured":"Practical Surgical Neuropathology. A Diagnostic Approach. 2nd ed. Philadelphia: Elsevier; 2018.","edition":"2"},{"key":"802_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/B978-0-12-802997-8.00005-0","volume":"134","author":"A Perry","year":"2016","unstructured":"Perry A, Wesseling P. Histologic classification of gliomas. Handb Clin Neurol. 2016;134:71\u201395.","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"802_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00401-015-1424-1","volume":"129","author":"P Wesseling","year":"2015","unstructured":"Wesseling P, van den Bent M, Perry A. Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):809\u201327.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"802_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00401-016-1657-7","volume":"133","author":"F Sahm","year":"2017","unstructured":"Sahm F, Korshunov A, Schrimpf D, Stichel D, Jones DT, Capper D, et al. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathol. 2017;133(2):325\u20137.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"802_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bpa.12295","volume":"26","author":"S Alexandrescu","year":"2016","unstructured":"Alexandrescu S, Korshunov A, Lai SH, Dabiri S, Patil S, Li R, et al. Epithelioid glioblastomas and anaplastic epithelioid pleomorphic Xanthoastrocytomas--same entity or first cousins? Brain Pathol. 2016;26(2):215\u201323.","journal-title":"Brain Pathol"},{"issue":"5","key":"802_CR35","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bpa.12566","volume":"28","author":"A Korshunov","year":"2018","unstructured":"Korshunov A, Chavez L, Sharma T, Ryzhova M, Schrimpf D, Stichel D, et al. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol. 2018;28(5):656\u201362.","journal-title":"Brain Pathol"},{"issue":"3","key":"802_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00401-010-0725-7","volume":"120","author":"MJ Bent van den","year":"2010","unstructured":"van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol. 2010;120(3):297\u2013304.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"802_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/jnen\/60.3.248","volume":"60","author":"C Giannini","year":"2001","unstructured":"Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001;60(3):248\u201362.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"802_CR38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00401-014-1326-7","volume":"128","author":"F Sahm","year":"2014","unstructured":"Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128(4):551\u20139.","journal-title":"Acta Neuropathol"},{"key":"802_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40478-015-0270-7","volume":"4","author":"BH Hinrichs","year":"2016","unstructured":"Hinrichs BH, Newman S, Appin CL, Dunn W, Cooper L, Pauly R, et al. Farewell to GBM-O: genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. Acta Neuropathol Commun. 2016;4:4.","journal-title":"Acta Neuropathol Commun."},{"issue":"1","key":"802_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00401-014-1359-y","volume":"129","author":"JT Huse","year":"2015","unstructured":"Huse JT, Diamond EL, Wang L, Rosenblum MK. Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true \"oligoastrocytoma\"? Acta Neuropathol. 2015;129(1):151\u20133.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"802_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00401-014-1353-4","volume":"129","author":"P Wilcox","year":"2015","unstructured":"Wilcox P, Li CC, Lee M, Shivalingam B, Brennan J, Suter CM, et al. Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathol. 2015;129(1):147\u20139.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"802_CR42","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u201373.","journal-title":"N Engl J Med"},{"issue":"8","key":"802_CR43","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1101\/gad.217406.113","volume":"27","author":"JA Losman","year":"2013","unstructured":"Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27(8):836\u201352.","journal-title":"Genes Dev"},{"issue":"12","key":"802_CR44","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1101\/gr.132738.111","volume":"22","author":"CG Duncan","year":"2012","unstructured":"Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, et al. A heterozygous IDH1R132H\/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 2012;22(12):2339\u201355.","journal-title":"Genome Res"},{"issue":"8","key":"802_CR45","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/PAS.0b013e3181e7740d","volume":"34","author":"D Capper","year":"2010","unstructured":"Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol. 2010;34(8):1199\u2013204.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"802_CR46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00401-009-0595-z","volume":"118","author":"D Capper","year":"2009","unstructured":"Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118(5):599\u2013601.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"802_CR47","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1093\/neuonc\/nou097","volume":"16","author":"L Chen","year":"2014","unstructured":"Chen L, Voronovich Z, Clark K, Hands I, Mannas J, Walsh M, et al. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro-Oncology. 2014;16(11):1478\u201383.","journal-title":"Neuro-Oncology"},{"issue":"12","key":"802_CR48","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/neuonc\/nox120","volume":"19","author":"JC DeWitt","year":"2017","unstructured":"DeWitt JC, Jordan JT, Frosch MP, Samore WR, Iafrate AJ, Louis DN, et al. Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro-Oncology. 2017;19(12):1640\u201350.","journal-title":"Neuro-Oncology"},{"issue":"10","key":"802_CR49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1097\/01.jnen.0000235122.98052.8f","volume":"65","author":"CA Griffin","year":"2006","unstructured":"Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol. 2006;65(10):988\u201394.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"20","key":"802_CR50","doi-asserted-by":"publisher","first-page":"9852","DOI":"10.1158\/0008-5472.CAN-06-1796","volume":"66","author":"RB Jenkins","year":"2006","unstructured":"Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66(20):9852\u201361.","journal-title":"Cancer Res"},{"key":"802_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.humpath.2017.05.005","volume":"69","author":"LY Ballester","year":"2017","unstructured":"Ballester LY, Huse JT, Tang G, Fuller GN. Molecular classification of adult diffuse gliomas: conflicting IDH1\/IDH2, ATRX, and 1p\/19q results. Hum Pathol. 2017;69:15\u201322.","journal-title":"Hum Pathol"},{"issue":"7","key":"802_CR52","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/neuonc\/nop075","volume":"12","author":"AP Vogazianou","year":"2010","unstructured":"Vogazianou AP, Chan R, Backlund LM, Pearson DM, Liu L, Langford CF, et al. Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro-Oncology. 2010;12(7):664\u201378.","journal-title":"Neuro-Oncology"},{"key":"802_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-020712-164030","volume":"8","author":"L Xu","year":"2013","unstructured":"Xu L, Li S, Stohr BA. The role of telomere biology in cancer. Annu Rev Pathol. 2013;8:49\u201378.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"802_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-016-2349-9","volume":"132","author":"J Lee","year":"2017","unstructured":"Lee J, Solomon DA, Tihan T. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. J Neuro-Oncol. 2017;132(1):1\u201311.","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"802_CR55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57\u201370.","journal-title":"Cell."},{"key":"802_CR56","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1038\/ncomms3185","volume":"4","author":"J Vinagre","year":"2013","unstructured":"Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.","journal-title":"Nat Commun"},{"issue":"6","key":"802_CR57","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00401-013-1195-5","volume":"126","author":"C Koelsche","year":"2013","unstructured":"Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126(6):907\u201315.","journal-title":"Acta Neuropathol"},{"issue":"15","key":"802_CR58","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1073\/pnas.1303607110","volume":"110","author":"PJ Killela","year":"2013","unstructured":"Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6238","key":"802_CR59","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1126\/science.aab0015","volume":"348","author":"RJ Bell","year":"2015","unstructured":"Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015;348(6238):1036\u20139.","journal-title":"Science"},{"issue":"4","key":"802_CR60","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12022-018-9551-6","volume":"29","author":"JO Paulsson","year":"2018","unstructured":"Paulsson JO, Olander A, Haglund F, Zedenius J, Juhlin CC. TERT immunohistochemistry is a poor predictor of TERT promoter mutations and gene expression in follicular thyroid carcinoma. Endocr Pathol. 2018;29(4):380\u20133.","journal-title":"Endocr Pathol"},{"issue":"1","key":"802_CR61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/bjc.2017.384","volume":"118","author":"E Hugdahl","year":"2018","unstructured":"Hugdahl E, Kalvenes MB, Mannelqvist M, Ladstein RG, Akslen LA. Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma. Br J Cancer. 2018;118(1):98\u2013105.","journal-title":"Br J Cancer"},{"key":"802_CR62","doi-asserted-by":"publisher","first-page":"7945845","DOI":"10.1155\/2018\/7945845","volume":"2018","author":"K Masui","year":"2018","unstructured":"Masui K, Komori T, Kato Y, Masutomi K, Ichimura K, Ogasawara S, et al. Elevated TERT expression in TERT-wildtype adult diffuse gliomas: histological evaluation with a novel TERT-specific antibody. Biomed Res Int. 2018;2018:7945845.","journal-title":"Biomed Res Int"},{"issue":"6","key":"802_CR63","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S1470-2045(13)70110-4","volume":"14","author":"P Castelo-Branco","year":"2013","unstructured":"Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T, et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. The Lancet Oncology. 2013;14(6):534\u201342.","journal-title":"The Lancet Oncology"},{"issue":"22","key":"802_CR64","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1158\/0008-5472.CAN-16-0696","volume":"76","author":"S Ohba","year":"2016","unstructured":"Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, et al. Mutant IDH1 expression drives TERT promoter reactivation as part of the cellular transformation process. Cancer Res. 2016;76(22):6680\u20139.","journal-title":"Cancer Res"},{"issue":"12","key":"802_CR65","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/ng.3438","volume":"47","author":"LJ Valentijn","year":"2015","unstructured":"Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015;47(12):1411\u20134.","journal-title":"Nat Genet"},{"issue":"4","key":"802_CR66","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/path.4672","volume":"238","author":"S Piscuoglio","year":"2016","unstructured":"Piscuoglio S, Ng CK, Murray M, Burke KA, Edelweiss M, Geyer FC, et al. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression. J Pathol. 2016;238(4):508\u201318.","journal-title":"J Pathol"},{"issue":"11","key":"802_CR67","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/modpathol.2013.90","volume":"26","author":"M Abedalthagafi","year":"2013","unstructured":"Abedalthagafi M, Phillips JJ, Kim GE, Mueller S, Haas-Kogen DA, Marshall RE, et al. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas. Mod Pathol. 2013;26(11):1425\u201332.","journal-title":"Mod Pathol"},{"issue":"1","key":"802_CR68","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnen\/nlv009","volume":"75","author":"J Tanboon","year":"2016","unstructured":"Tanboon J, Williams EA, Louis DN. The diagnostic use of Immunohistochemical surrogates for signature molecular genetic alterations in gliomas. J Neuropathol Exp Neurol. 2016;75(1):4\u201318.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"802_CR69","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bpa.12173","volume":"25","author":"H Takami","year":"2015","unstructured":"Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, et al. Revisiting TP53 mutations and immunohistochemistry--a comparative study in 157 diffuse gliomas. Brain Pathol. 2015;25(3):256\u201365.","journal-title":"Brain Pathol"},{"issue":"3","key":"802_CR70","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/PAP.0b013e3181d98cd9","volume":"17","author":"E Dunbar","year":"2010","unstructured":"Dunbar E, Yachnis AT. Glioma diagnosis: immunohistochemistry and beyond. Adv Anat Pathol. 2010;17(3):187\u2013201.","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"802_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00401-014-1370-3","volume":"129","author":"DE Reuss","year":"2015","unstructured":"Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an \"integrated\" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133\u201346.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"802_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11060-016-2296-5","volume":"131","author":"M Mellai","year":"2017","unstructured":"Mellai M, Annovazzi L, Senetta R, Dell'Aglio C, Mazzucco M, Cassoni P, et al. Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1\/2 and 1p\/19q status. J Neuro-Oncol. 2017;131(2):213\u201322.","journal-title":"J Neuro-Oncol"},{"issue":"20","key":"802_CR73","first-page":"6962","volume":"63","author":"N Shinojima","year":"2003","unstructured":"Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63(20):6962\u201370.","journal-title":"Cancer Res"},{"issue":"21","key":"802_CR74","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1111\/febs.12393","volume":"280","author":"HK Gan","year":"2013","unstructured":"Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013;280(21):5350\u201370.","journal-title":"FEBS J"},{"issue":"3","key":"802_CR75","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11060-017-2606-6","volume":"135","author":"DB Koshiyama","year":"2017","unstructured":"Koshiyama DB, Trevisan P, Graziadio C, Rosa RFM, Cunegatto B, Scholl J, et al. Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p\/19q deficiency in a sample of adult patients diagnosed with glioblastoma from southern Brazil. J Neuro-Oncol. 2017;135(3):465\u201372.","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"802_CR76","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jmoldx.2011.06.003","volume":"13","author":"I Crespo","year":"2011","unstructured":"Crespo I, Vital AL, Nieto AB, Rebelo O, Tao H, Lopes MC, et al. Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. J Mol Diagn. 2011;13(6):634\u201347.","journal-title":"J Mol Diagn"},{"issue":"10","key":"802_CR77","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"issue":"10","key":"802_CR78","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"2","key":"802_CR79","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/neuonc\/noy132","volume":"21","author":"Alireza Mansouri","year":"2018","unstructured":"Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 2018;21(2):167\u201378.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"802_CR80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/ng0997-32","volume":"17","author":"J Mollenhauer","year":"1997","unstructured":"Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet. 1997;17(1):32\u20139.","journal-title":"Nat Genet"},{"issue":"8","key":"802_CR81","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/NEN.0b013e31825f2e5d","volume":"71","author":"K Motomura","year":"2012","unstructured":"Motomura K, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, et al. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome. J Neuropathol Exp Neurol. 2012;71(8):702\u20137.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"802_CR82","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1215\/15228517-2008-064","volume":"10","author":"D Kuga","year":"2008","unstructured":"Kuga D, Mizoguchi M, Guan Y, Hata N, Yoshimoto K, Shono T, et al. Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues. Neuro-Oncology. 2008;10(6):995\u20131003.","journal-title":"Neuro-Oncology"},{"issue":"7384","key":"802_CR83","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226\u201331.","journal-title":"Nature"},{"issue":"3","key":"802_CR84","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","volume":"44","author":"G Wu","year":"2012","unstructured":"Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44(3):251\u20133.","journal-title":"Nat Genet"},{"issue":"6","key":"802_CR85","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","volume":"130","author":"D Castel","year":"2015","unstructured":"Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015;130(6):815\u201327.","journal-title":"Acta Neuropathol"},{"issue":"6134","key":"802_CR86","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1126\/science.1232245","volume":"340","author":"PW Lewis","year":"2013","unstructured":"Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340(6134):857\u201361.","journal-title":"Science."},{"issue":"5","key":"802_CR87","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/bpa.12336","volume":"26","author":"DA Solomon","year":"2016","unstructured":"Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the Spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26(5):569\u201380.","journal-title":"Brain Pathol"},{"issue":"5","key":"802_CR88","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00401-014-1338-3","volume":"128","author":"S Venneti","year":"2014","unstructured":"Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, et al. A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol. 2014;128(5):743\u201353.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"802_CR89","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40478-018-0614-1","volume":"6","author":"D Castel","year":"2018","unstructured":"Castel D, Philippe C, Kergrohen T, Sill M, Merlevede J, Barret E, et al. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. Acta Neuropathol Commun. 2018;6(1):117.","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"802_CR90","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","volume":"27","author":"KW Pajtler","year":"2015","unstructured":"Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728\u201343.","journal-title":"Cancer Cell"},{"issue":"5","key":"802_CR91","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00401-017-1752-4","volume":"134","author":"P Panwalkar","year":"2017","unstructured":"Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-a childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol. 2017;134(5):705\u201314.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"802_CR92","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00401-018-1805-3","volume":"135","author":"D Pratt","year":"2018","unstructured":"Pratt D, Natarajan SK, Banda A, Giannini C, Vats P, Koschmann C, et al. Circumscribed\/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathol. 2018;135(2):299\u2013301.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"802_CR93","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bpa.12455","volume":"27","author":"BK Kleinschmidt-DeMasters","year":"2017","unstructured":"Kleinschmidt-DeMasters BK, Donson A, Foreman NK, Dorris K. H3 K27M mutation in Gangliogliomas can be associated with poor prognosis. Brain Pathol. 2017;27(6):846\u201350.","journal-title":"Brain Pathol"},{"issue":"1","key":"802_CR94","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/bpa.12473","volume":"28","author":"M Pages","year":"2018","unstructured":"Pages M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, et al. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathol. 2018;28(1):103\u201311.","journal-title":"Brain Pathol"},{"issue":"3","key":"802_CR95","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/nan.12329","volume":"43","author":"N Joyon","year":"2017","unstructured":"Joyon N, Tauziede-Espariat A, Alentorn A, Giry M, Castel D, Capelle L, et al. K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway. Neuropathol Appl Neurobiol. 2017;43(3):271\u20136.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"802_CR96","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00401-015-1493-1","volume":"131","author":"A Korshunov","year":"2016","unstructured":"Korshunov A, Capper D, Reuss D, Schrimpf D, Ryzhova M, Hovestadt V, et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol. 2016;131(1):137\u201346.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"802_CR97","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11060-012-1040-z","volume":"112","author":"M Gessi","year":"2013","unstructured":"Gessi M, Gielen GH, Hammes J, Dorner E, Muhlen AZ, Waha A, et al. H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? J Neuro-Oncol. 2013;112(1):67\u201372.","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"802_CR98","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","volume":"120","author":"C Hartmann","year":"2010","unstructured":"Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707\u201318.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"802_CR99","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00401-016-1620-7","volume":"132","author":"D Unruh","year":"2016","unstructured":"Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol. 2016;132(6):917\u201330.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"802_CR100","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00401-015-1454-8","volume":"130","author":"DE Reuss","year":"2015","unstructured":"Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015;130(3):407\u201317.","journal-title":"Acta Neuropathol"},{"issue":"10","key":"802_CR101","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/neuonc\/nox078","volume":"19","author":"A Aibaidula","year":"2017","unstructured":"Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R, et al. Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology. 2017;19(10):1327\u201337.","journal-title":"Neuro-Oncology"},{"issue":"5","key":"802_CR102","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00401-018-1905-0","volume":"136","author":"D Stichel","year":"2018","unstructured":"Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 2018;136(5):793\u2013803.","journal-title":"Acta Neuropathol"},{"issue":"7697","key":"802_CR103","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469\u201374.","journal-title":"Nature."},{"issue":"2","key":"802_CR104","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00401-018-1879-y","volume":"136","author":"D Capper","year":"2018","unstructured":"Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018;136(2):181\u2013210.","journal-title":"Acta Neuropathol"},{"key":"802_CR105","doi-asserted-by":"publisher","unstructured":"Lee M, Kang SY, Suh YL. Genetic alterations of epidermal growth factor receptor in glioblastoma: the usefulness of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2018. \n                    https:\/\/doi.org\/10.1097\/PAI.0000000000000669\n                    \n                  .","DOI":"10.1097\/PAI.0000000000000669"},{"issue":"6","key":"802_CR106","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00401-016-1539-z","volume":"131","author":"I Qaddoumi","year":"2016","unstructured":"Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 2016;131(6):833\u201345.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"802_CR107","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00401-018-1837-8","volume":"136","author":"A Reinhardt","year":"2018","unstructured":"Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE, et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations. Acta Neuropathol. 2018;136(2):273\u201391.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"802_CR108","first-page":"699","volume":"19","author":"CN Kline","year":"2017","unstructured":"Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro-Oncology. 2017;19(5):699\u2013709.","journal-title":"Neuro-Oncology"},{"issue":"3","key":"802_CR109","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/neuonc\/nov289","volume":"18","author":"MN Nikiforova","year":"2016","unstructured":"Nikiforova MN, Wald AI, Melan MA, Roy S, Zhong S, Hamilton RL, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro-Oncology. 2016;18(3):379\u201387.","journal-title":"Neuro-Oncology"},{"issue":"6","key":"802_CR110","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00401-015-1519-8","volume":"131","author":"F Sahm","year":"2016","unstructured":"Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131(6):903\u201310.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"802_CR111","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bpa.12367","volume":"27","author":"A Zacher","year":"2017","unstructured":"Zacher A, Kaulich K, Stepanow S, Wolter M, Kohrer K, Felsberg J, et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel. Brain Pathol. 2017;27(2):146\u201359.","journal-title":"Brain Pathol"},{"issue":"10","key":"802_CR112","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/neuonc\/nov015","volume":"17","author":"SH Ramkissoon","year":"2015","unstructured":"Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, et al. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology. 2015;17(10):1344\u201355.","journal-title":"Neuro-Oncology"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-019-0802-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T19:06:08Z","timestamp":1586286368000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-019-0802-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1186\/s13000-019-0802-8","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Clinical data and photomicrographs are gathered under a Neurosurgery\/Neuropathology Data Repository, which has been approved by the Oregon Health & Science University Institutional Review Board, with a waiver of patient consent (STUDY0018895).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"29"}}